FH
Foghorn Therapeutics Inc.
FHTX · NASDAQ
$4.67 -1.89% (-$0.09)
1M -22.60%
Market Cap $283.6M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
8 /100
Expensive P/S 7.72x
EV/EBITDA N/A
P/B N/A
Growth
96 /100
Growing Rev. growth 17.14%
FCF growth N/A
Book val. growth N/A
Profitability
17 /100
Weak Net margin 175.78%
Op. margin 186.38%
FCF margin 232.31%
Quality
3 /100
Poor ROA 31.75%
Asset turnover 0.18x
ROIC 44.00%
Debt
100 /100
Low Current ratio 3.36x
Int. coverage N/A
Net debt/EBITDA N/A
Stability
31 /100
Unstable Rev. volatility 56.38%
EPS volatility 11.11%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FHTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Adrian H. Gottschalk
Employees
106
Headquarters
Watertown
Upcoming events
04 NOV
Earnings
Upcoming earnings report